Also, FDA launches Oncology Center of Excellence, Siemens has allocated more than $1 billion to its Next47 unit to work with startups with disruptive technology, Harvard Pilgrim Health Care is reimbursing for telemedicine through a deal with Doctor On Demand.
The Biosimilars Forum’s senior policy advisor, Michael Werner — who is also a partner at the law firm of Holland and Knight — talked with MedCity News about what’s going on with biosimilars.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Biosimilars compete directly with branded biologics that are now going off patent - and in five years, they'll account for 20 percent of the global pharmaceutical market.
The company is raising $50 million, on top of some $43 million it's raised this year, according to regulatory filings.
Avitide, a New Hampshire biotech startup, just raised a $7.5 million Series C for its lithe protein engineering platform that can purify and develop biologics and biosimilars.
New Jersey biosimilar maker Oncobiologics just raised $31 million. It's developing biosimilars for 11 monoclonal antibody drugs that will soon go off-patent, such as Humira, Avastin and Herceptin.
This eBook, in collaboration with Care Logistics, details how hospitals and health systems can facilitate more effective decision-making by operationalizing elevated awareness.
On Friday, the Food and Drug Administration approved the first biosimilar, marking an initial big step foward in changing the climate of the drug market in the United States. Time to save some money. Zarxio, produced by Sandoz, Inc. – a division of Novartis, is a drug that is designed to help the body produce […]
The advancement of biosimilars moves another step forward today with the launch of versions of a rheumatoid arthritis and Crohn’s disease drug to European markets. The products, which come from South Korean firm Celltrion and its partners Hospira and Mundipharma, will be in competition with the Johnson & Johnson and Merck & Co. drug Remicade. […]
Worldwide growth in the biosimilars market is hitting its tipping point, analysts say. Sales are projected to hit $25 billion by 2020, according to the folks over at BioWorld who put together a new report, “Biosimilars: A Global Perspective of a New Market.” This is pretty impressive projected growth, considering that total global sales of drugs approved […]
In a move that heralds greater momentum toward regulating biosimilars, the Food and Drug Administration has published its first-ever “Purple Book” – a list of all FDA-licensed biologics and the biosimilars that can be used in their stead. It’s meant to be equivalent to the FDA’s “Orange Book” – the go-to list for physicians, regulatory agents and […]
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
Generic drugs have been an effective cost containment solution for traditional, small molecule pharmaceuticals. As large molecule biologics proliferate and take up a growing share of medical spending, we also increasingly need cost containment. The path we’re on now in the US and Europe is to ape the experience with small molecule products by introducing [...]